Review of ginsenosides targeting mitochondrial function to treat multiple disorders: Current status and perspectives

Qingxia Huang 1,2, Song Gao 3, Daqing Zhao 1,4,5, *, Xiangyan Li 1,4,5, *

1 Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, Jilin, China
2 Key Laboratory of Active Substances and Biological Mechanisms of Ginseng Efficacy, Ministry of Education, Changchun University of Chinese Medicine, Changchun, Jilin, China
3 Jilin Ginseng Academy, Key Laboratory of Bio-Macromolecules of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China
4 Jilin Provincial Key Laboratory of Bio-Macromolecules of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China
5 Jilin Provincial Key Laboratory of Bio-Macromolecules of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China

A R T I C L E   I N F O
Article history:
Received 22 April 2020
Received in revised form 8 November 2020
Accepted 9 December 2020
Available online 11 December 2020

Keywords:
ginsenosides
mitochondria
neurological disorder
cancer
heart disease

A B S T R A C T
Mitochondrial dysfunction contributes to the pathogenesis and prognosis of many common disorders, including neurodegeneration, stroke, myocardial infarction, tumor, and metabolic diseases. Ginsenosides, the major bioactive constituents of Panax ginseng (P. ginseng), have been reported to play beneficial roles in the molecular pathophysiology of these diseases by targeting mitochondrial dysfunction. In this review, we first introduce the types of ginsenosides and basic mitochondrial functions. Then, recent findings are summarized on different ginsenosides targeting mitochondria and their key signaling pathways for the treatment of multiple diseases, including neurological disorders, cancer, heart disease, hyperglycemia, and inflammation are summarized. This review may explain the common targets of ginsenosides against multiple diseases and provide new insights into the underlying mechanisms, facilitating research on the clinical application of P. ginseng.

© 2020 The Korean Society of Ginseng. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Panax ginseng (P. ginseng) has tonifying effects on important organs, maintaining their function and strengthens vitality and body resistance to inhibit physiological aging and withstand pathological stresses [1]. P. ginseng contains various pharmacological ingredients, such as ginsenosides, polysaccharides, polyphenols, and polyacetylenes [2]. Among them, ginsenosides are recognized as the major bioactive ingredients. The beneficial effects of ginsenosides have been extensively investigated, and various bioactivities have been identified, such as neuroprotection, cardioprotection, anti-tumor, anti-diabetes, and anti-inflammation and so on [3]. However, it remains unclear whether the beneficial effects of ginsenosides on various diseases are mediated by a common functional mechanism.

The mitochondria, a cytoplasmic double-membrane organelle, plays a crucial role in cell physiological processes, including energy homeostasis, autophagy, oxidative stress balance, and apoptotic signaling cascades [4]. Mitochondrial homeostasis dysfunction or disruption also contributes to the pathogenesis of many disorders, including neurodegeneration, stroke, myocardial infarction, cancer, and metabolic diseases [5]. Importantly, a large number of results from in vitro and in vivo studies have confirmed the beneficial effects of ginsenosides for preventing and treating various diseases are related to their interference with mitochondrial dysfunction [6–8].

To better understand how ginsenosides regulate mitochondrial function and its related signaling pathways to elicit their multiple pharmacological effects in mammalian cells, we summarize recent findings with respect to ginsenosides targeting mitochondrial...
function in multiple disorders. First, we briefly introduce ginsenosides and the biological functions of mitochondria. Then, the roles of different ginsenosides in regulating mitochondrial biogenesis, bioenergetics, autophagy, motility, and apoptosis for the treatment of different diseases are summarized. For example, different ginsenosides have been reported to prevent acute and chronic diseases by influencing the opening of mitochondrial permeability transition pores (mPTPs), balancing reactive oxygen species (ROS), modulating mitochondrial fission and fusion, or mediating mitophagy [9]. A thorough understanding of the effects of ginsenosides on mitochondrial function and its key signaling pathways is necessary to explain how the main components of P. ginseng treat multiple diseases and to comprehensively explore the molecular mechanisms by which P. ginseng treats multiple diseases.

2. Ginsenosides

Ginsenosides, a type of steroidal saponins, have a dammarane-type triterpenoid structure and a four-ring hydrophobic steroidal-like structure conjugated with sugar moieties, which are divided into three different structural classes: protopanaxadiol (PPD-type), protopanaxatriol (PPT-type), and oleanolic acid (OA-type) groups [10]. PPD-type ginsenosides, including ginsenosides Rb1 (Rb1), ginsenosides Rb2 (Rb2), ginsenosides Rb3 (Rb3), ginsenosides Rc (Rc), ginsenosides Rd (Rd), ginsenosides Rg3 (Rg3), and ginsenosides Rh2 (Rh2), have conjugated sugar moieties attached to the 3-position of the triterpenoid dammarane structure, whereas PPT-type ginsenosides, including ginsenosides Re (Re), ginsenosides Rf (Rf), ginsenosides Rg1 (Rg1), and ginsenosides Rh1 (Rh1), have sugar moieties attached to the 6-position of the triterpenoid dammarane structure [11]. Quantitative and qualitative analysis for ginsenosides in vivo revealed that PPD-type ginsenosides exhibit higher plasma concentrations and longer half-lives than PPT-type ginsenosides [12]. Meanwhile, the absorption rate of intact ginsenosides in the intestines is as low as 1% to 3.7%, and most of them are metabolized and converted into other ginsenosides through acid hydrolysis in the stomach and bacterial hydrolysis in the intestine [12]. To date, more than 200 different natural and transformed ginsenosides and their metabolites have been identified and studied in a variety of pathological conditions [8,9].

3. Mitochondrial dysfunction

Mitochondria are responsible for the physiological and pathological processes of aerobic respiration-based cells in mammalian, including oxidative phosphorylation (OXPHOS), the biosynthesis of intermediates for cell growth, and the metabolism of three major nutrients (glucose, amino acids, and fatty acids), and also mediate the essential processes that determine cell function and status [13]. Mitochondrial dysfunction is found in many diseases, including neurodegeneration, cancer, metabolic diseases, heart failure, and ischemia-reperfusion (I/R) injury, which have been reported in some reviews [14]. Numerous studies have shown that ginsenosides can regulate mitochondrial (mito)-ROS, mito-apoptosis, mito-bioenergetics, mito-biogenesis, mito-dynamics, and mitophagy to exert pharmacological effects, which have been summarized in Fig. 1.

4. Ginsenosides target mitochondria, treating different diseases

Some studies have demonstrated that ginsenosides act as protective agents of mitochondrial function, mainly by direct or indirect enhancement of mitochondrial biosynthesis, mitophagy, or electron transport chain (ETC) efficiency or inhibition of mito-ROS [8,15]. Conversely, ginsenosides also can treat cancer and other diseases by promoting mito-apoptosis and mitophagy [9,16]. In the models of different diseases, including nervous system disorders, cardiovascular system disorders, and tumors, different ginsenoside monomers cause mitochondrial function alterations by regulating transcription factors, the expression of mitochondria-related genes, and mitochondrial dysfunction pathway networks, which are discussed here (Fig. 2).
4.1. Neurological disorders

In the resting state of the human body, the brain consumes 20% of body energy, although it only has 2% of the total body mass [17]. Mitochondrial function can directly influence neuronal function, such as synaptic plasticity, axonal transport, and the release of neurotransmitters, and abnormal mitochondrial function in neurons precedes neurological changes and neuronal loss [18]. Multiple neurological diseases have been associated with mitochondrial dysfunction, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and ischemic stroke. Ginsenoside monomers can target different functions of mitochondria to preventing and treating neurological disorders [19–21].

4.1.1. Parkinson’s disease

Mitochondrial dysfunction plays key roles in PD initiation and progression. In 1-methyl-4-phenylpyridinium-induced human neuroblastoma SH-SY5Y cells and Parkinsonian toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models, Rd shows a significant neuroprotective effect by enhancing antioxidant enzymatic activities, preserving the activity of ETC complex I, stabilizing the mitochondrial membrane permeabilization (MMP), and increasing intracellular ATP levels [19]. Additionally, the PI3K/Akt signaling pathway is involved in the protective effect of Rd against PD. In a rotenone-induced PD neuronal model with mitochondrial dysfunction, the combination of Rd with Re attenuates the extent of depolarization of MMP and restores calcium levels by modulating the Bcl2/Bax ratio and inhibiting the release of Cyto C and caspase-3 activation [22]. These findings highlight the efficacies of Rd and Re in the prevention and treatment of PD through improving mitochondrial integrity and ETC efficiency, and inhibiting mito-apoptosis.

4.1.2. Alzheimer’s disease

In Aβ peptide-treated neuroblastoma cells, proteomic analysis shows that Rg1 can alter the expression of 49 mitochondrial proteins, such as 3-hydroxyacyl-CoA dehydrogenase type-2, alanine-tRNA ligase, mitochondrial import receptor subunit TOM40 homolog, and Cyto C oxidase subunit 5A [23]. Moreover, the pretreatment of primary cultured cortical neurons with Rg1 (20 μM) for 24 h and exposure to 10 μM Aβ for 72 h can elevate the Bcl2/Bax ratio, reduce Cyto C release from mitochondria into the cytoplasm, and then block mitochondrial apoptotic cascades after Aβ insult [24].

Metabolomic and apoptotic analysis for Rg3-administered AD rats shows that Rg3 could prevent cognitive impairment by regulating the abnormality of energy metabolism, ETC efficiency, amino acid metabolism, and purine metabolism and regulating mitochondrial apoptosis [20]. Re, another ginsenoside, inhibits the ROS/ASK-1-dependent mito-apoptotic pathway in Aβ- and colistin-treated SH-SY5Y cells through the inhibition of the apoptosis-related pathway (the elevation of the Bcl2/Bax ratio and the reduction of Cyto release) and ROS production [25]. These results indicate that multiple ginsenoside monomers promote energy metabolism and inhibit the mitochondrial apoptosis by increasing ETC function in AD.

4.1.3. Ischemic stroke

In middle cerebral artery occlusion (MCAO) rat models, Rd administration reduces mtDNA damage and the cleavage of caspase-3, improving the survival rate and neurological function 7 days after MCAO [26]. Rd also protects against mitochondrial damage after reperfusion by preserving ETC activity and aconitase activity, which decreasing mitochondrial hydrogen peroxide production and depolarizing MMP in the aged MCAO mice [21]. In addition, the results from in vitro and in vivo models of cerebral ischemia demonstrate that Rd markedly decreases the secretion of lactate and attenuates mitochondrial swelling by preserving MMP and reducing the mitochondrial release of Cyto C and ROS production to minimize mitochondria-mediated apoptosis following ischemia [27].

In an oxygen–glucose deprivation/reoxygenation-induced primary mouse astrocyte injury model, Rb1 and Rg1 co-treatment decreases the mtDNA copy number and the MMP depolarization, and increases the activities of ETC complexes I, II, III, and V, promoting the production of ATP [28]. The results above show that ginsenoside monomers reduce ischemic stroke damage by enhancing ETC activity and inhibiting mitochondrial apoptosis.

4.1.4. Neuronal injury

The neuroprotective effect of ginsenosides is also closely related to mitochondrial function. Re treatment significantly attenuates phencyclidine-induced mitochondrial oxidative stress and ETC dysfunction by regulating NADPH oxidase activity in mouse dorsolateral cortex neurons [29]. Re also protects methamphetamine-induced mitochondrial burdens (i.e., decrease of MMP, Cyto C release from mitochondria, and activation of caspase-3) via the inhibition of protein kinase C (PKC) in SH-SY5Y cells [30,31]. These Re-mediated protective effects are comparable to those observed in PKCδ knockdown (−/−) mice [30]. Mitochondrial quality control is regulated by successive rounds of fission, fusion, and mitophagy with the dynamic exchange of necessary components. Moon et al. reported that Rg3 can induce autophagy flux, attenuating human prion protein-mediated neurotoxicity and mitochondrial dysfunction in neuronal cells [32]. Furthermore, PPD inhibits mitochondrial morphological changes, scavenges the mito-ROS, improves MMP, and enhances mitochondrial counts compared with the cells exposed to glutamate only [33]. In the neurotoxicity model of PC12 cells induced by colistin, Rg1 also exerts neuroprotective effects via multiple apoptosis-related pathways, including the decreases of Cyto C release and caspase-3/9 cleavages [34]. In primary cultured rat hippocampal neurons, Rb1 inhibits the burst of intracellular ROS and the depolarization of MMP induced by high glucose [35]. In addition, Rb1 and Rg1 protect neuronal cells against MMP loss, mito-apoptosis, and aconitate inhibition induced by mitochondrial complex I inhibitor, rotenone, in an in vitro neuronal model of neurotoxicity, which may be mediated by NRF-2 activation [36].

Based on these studies, we found that in AD, PD, ischemic stroke, and various chemically induced neuronal injury models, ginsenoside monomers not only inhibit mito-apoptosis and mito-ROS, but also enhance mtDNA replication, NADPH oxidase, and mitophagy. The beneficial effects of different ginsenoside monomers on neurological disorders are summarized in Table 1.

4.2. Cancer

Many studies have shown that ginsenoside monomers can promote tumor cell death by activating mitochondrial apoptosis and autophagy (Table 2).

4.2.1. Compound K on tumors

Compound K (CK), a main intestinal bacterial metabolite of protopanaxadiol saponin, can inhibit various cancers by inducing mito-apoptosis, mito-ROS, and autophagy [37]. A recent study has shown that CK promotes autophagosome accumulation by inducing early-stage autophagy, and inhibits late-stage autophagy inducing mitochondria damage in in vitro and in vivo neuroblastoma models [37]. In human hepatocellular carcinoma MHCC97-H cells, CK treatment induces the reductions in MMP, mtDNA copy...
number, Bcl2/Bax ratio, and caspase-3/9 expression in an Akt phosphorylation-dependent manner [38]. Similarly, in human colon cancer HT-29 cells, CK induces a mito-apoptotic pathway by affecting Bax and Bcl2 expression, resulting in the depolarization of the MMP [39]. During cytotoxic apoptosis, the translocation of full-length Bid from cell nuclei to mitochondria directly causes the release of Cyto C from mitochondria, indicating that full-length Bid from cell nuclei to mitochondria directly causes the release of Cyto C from mitochondria into the cytoplasm, affecting Bax and Bcl2 expression, resulting in the depolarization of the MMP, enhances the release of Cyto C, and activates the cleavage of caspase-3 and procaspase-9, and increases the Bax/Bcl2 ratio by ROS generation and p38-MAPK activation [42].

4.2.2. Rg3 on tumors

Pretreatment with Rg3 decreases MMP and mito-apoptosis in HeLa cells by regulating autophagy [43]. In myeloma cells, Rg3 also induces apoptosis by altering the Bcl2/Bax ratio, caspase activation, and the release of Cyto C from the mitochondria into the cytoplasm through the IGF-1/Akt/mTOR pathway [44]. In human breast cancer, MDA-MB-231 cells, treatment with Rg3 (30 μM) increases the Bax/Bcl2 ratio, the depolarization of MMP, and the release of mitochondrial Cyto C and also induces the cleavage of caspase-3 and poly-(ADP-ribose) polymerase (PARP), which is attenuated by a caspase-3 inhibitor, Z-VAD-FMK, indicating that Rg3 induces breast cancer cell apoptosis via classical mitochondrial-dependent caspase activation [45]. Furthermore, in HT-29 colon cancer cells, Rg3 downregulates the expression of Bcl2 and upregulates the expression of the pro-apoptotic protein, p53 or Bax, thereby inducing the release of mitochondrial Cyto C and the cleavages of PARP, caspase-9, and caspase-3 through the AMPK signaling pathway [46]. Similarly, Rg3 exposure suppresses the survival of gallbladder cancer via the activation of the mitochondrial-mediated intrinsic apoptosis pathway in NOZ cells, GBC-SD cells, mitochondrial apoptosis and poly-(ADP-ribose) polymerase (PARP), which is attenuated by a caspase-3 inhibitor, Z-VAD-FMK, indicating that Rg3 induces breast cancer cell apoptosis via classical mitochondrial-dependent caspase activation [45]. Furthermore, in HT-29 colon cancer cells, Rg3 downregulates the expression of Bcl2 and upregulates the expression of the pro-apoptotic protein, p53 or Bax, thereby inducing the release of mitochondrial Cyto C and the cleavages of PARP, caspase-9, and caspase-3 through the AMPK signaling pathway [46]. Similarly, Rg3 exposure suppresses the survival of gallbladder cancer via the activation of the mitochondrial-mediated intrinsic apoptosis pathway in NOZ cells, GBC-SD cells, and nude mice [47]. In addition, in human hepatocellular carcinoma Hep3B cells, the combination of Rg3 and 20(S)−Rh2 decreases MMP, enhances the release of Cyto C, and activates the cleavage of caspase-3, which suggests that they may induce apoptosis by direct activation of the mitochondrial pathway [48]. Another study reported that Rg3 combined with Rh2 and 20(S)−Rh2 can induce mito-ROS and mito-apoptosis in human leukemia Jurkat cells [49].

Table 1

Summary of Mitochondria-Related Neurological Protective Effects of Ginsenosides

| Reference | Ginsenoside | Model | Inducer | Experimental model | Effects targeting mitochondria |
|-----------|-------------|-------|---------|-------------------|--------------------------------|
| [31]      | Rg3         | Neurological injury | Glutamate | T24                | MMP, Bcl2/Bax                 |
| [32]      | Rg3         | Neurological injury | Glutamate | T24                | MMP, Bcl2/Bax                 |
| [33]      | PPD         | Neurological injury | Glutamate | T24                | MMP, Bcl2/Bax                 |
| [34]      | Rg1         | Neurological injury | Glutamate | T24                | MMP, Bcl2/Bax                 |
| [35]      | Rb1         | Neurological injury | Glutamate | T24                | MMP, Bcl2/Bax                 |
| [36]      | Rb1, Rg1    | Neurological injury | Glutamate | T24                | MMP, Bcl2/Bax                 |

Table 2

Summary of Mitochondria-Related Antitumor Effects of Ginsenosides

| Reference | Ginsenoside | Model | Experimental model | Effects targeting mitochondria |
|-----------|-------------|-------|-------------------|--------------------------------|
| [37]      | CK          | Neuroblastoma cells | MMP | MMP, mitochondrial apoptosis |
| [38]      | CK          | Hepatocellular carcinoma cells (MHCC97-H) | MMP | MMP, mitochondrial apoptosis |
| [39]      | CK          | Colon cancer cells (HT-29) | MMP | MMP, mitochondrial apoptosis |
| [40]      | CK          | Bladder cancer cells (T24) | MMP | MMP, mitochondrial apoptosis |
| [41]      | Rg3         | HeLa cells | MMP | MMP, mitochondrial apoptosis |
| [42]      | Rg3         | Myeloma cells (U266, RPMI226, SKO-007) | MMP | MMP, mitochondrial apoptosis |
| [43]      | Rg3         | Breast cancer cells (MDA-MB-231) | MMP | MMP, mitochondrial apoptosis |
| [44]      | Rg3         | Colon cancer cells (HT-29) | MMP | MMP, mitochondrial apoptosis |
| [45]      | Rg3         | Gallbladder cancer cells | MMP | MMP, mitochondrial apoptosis |
| [46]      | Rg3         | Hepatocellular carcinoma cells (Hep3B) | MMP | MMP, mitochondrial apoptosis |
| [47]      | Rg3, Rh2    | Leukemia cells (Jurkat) | MMP | MMP, mitochondrial apoptosis |
| [48]      | Rh2         | Leukemia cells (lymphoblastic, Reh) | MMP | MMP, mitochondrial apoptosis |
| [49]      | Rh2         | Breast cancer cells (MCV-7, MDA-MB-231) | MMP | MMP, mitochondrial apoptosis |
| [50]      | Rh2         | Human esophageal cancer cells (Eca109) | MMP | MMP, mitochondrial apoptosis |
| [51]      | Rh2         | Breast cancer cells (HepG2) | MMP | MMP, mitochondrial apoptosis |
| [52]      | Rh2         | Breast cancer cells (HepG2) | MMP | MMP, mitochondrial apoptosis |
| [53]      | Rh2         | Breast cancer cells (HepG2) | MMP | MMP, mitochondrial apoptosis |
| [54]      | Rh5         | Breast cancer cells (MCF-7, MDA-MB-231) | MMP | MMP, mitochondrial apoptosis |
| [55]      | Rh5         | Breast cancer cells (Eca109) | MMP | MMP, mitochondrial apoptosis |
| [56]      | Rf2         | Gastric carcinoma cells | MMP | MMP, mitochondrial apoptosis |
| [57]      | Rg1         | Osteosarcoma cells (MG-63) | MMP | MMP, mitochondrial apoptosis |
| [58]      | Rg1         | Leukemia cells (K562) | MMP | MMP, mitochondrial apoptosis |
| [59]      | pseudo-Rh2  | Gastric cancer cells (SGC-7901) | MMP | MMP, mitochondrial apoptosis |

In addition, the release of Cyto C from mitochondria into the cytoplasm through the IGF-1/Akt/mTOR pathway [44]. In human breast cancer, MDA-MB-231 cells, treatment with Rg3 (30 μM) increases the Bax/Bcl2 ratio, the depolarization of MMP, and the release of mitochondrial Cyto C and also induces the cleavage of caspase-3 and poly-(ADP-ribose) polymerase (PARP), which is attenuated by a caspase-3 inhibitor, Z-VAD-FMK, indicating that Rg3 induces breast cancer cell apoptosis via classical mitochondrial-dependent caspase activation [45]. Furthermore, in HT-29 colon cancer cells, Rg3 downregulates the expression of Bcl2 and upregulates the expression of the pro-apoptotic protein, p53 or Bax, thereby inducing the release of mitochondrial Cyto C and the cleavages of PARP, caspase-9, and caspase-3 through the AMPK signaling pathway [46]. Similarly, Rg3 exposure suppresses the survival of gallbladder cancer via the activation of the mitochondrial-mediated intrinsic apoptosis pathway in NOZ cells, GBC-SD cells, and nude mice [47]. In addition, in human hepatocellular carcinoma Hep3B cells, the combination of Rg3 and 20(S)−Rh2 decreases MMP, enhances the release of Cyto C, and activates the cleavage of caspase-3, which suggests that they may induce apoptosis by direct activation of the mitochondrial pathway [48]. Another study reported that Rg3 combined with Rh2 and 20(S)−Rh2 can induce mito-ROS and mito-apoptosis in human leukemia Jurkat cells [49].
4.2.3. 20(S)–Rh2 on tumors

Mitophagy inhibition could aggravate mito-ROS generation and mitochondrial function and accelerate mito-apoptosis. Xia et al. have shown that mitophagy plays a protective role in 20(S)–Rh2-induced apoptosis in human acute lymphoblastic leukemia (ALL) cell lines and primary ALL cells via mito-apoptosis and autophagy without cytotoxic effects on normal blood cells [50]. In liver cancer HepG2 cells, 20(S)–Rh2 incubation induces apoptosis by increasing the accumulation of ROS and the activation of the lysosomal-mitochondrial apoptotic pathway [51]. 20(S)–Rh2 can also induce MMP of human leukemia Reh cells in the shift in JC-1 fluorescence from red to green and cause the release of mitochondrial Cyto C and activation of cleaved caspase-9 and caspase-3 [52]. In human breast cancer cell lines and in vivo xenograft models, 20(S)–Rh2-induced apoptosis is accompanied by the downregulation of anti-apoptotic proteins, Bcl2, Bcl-xl, and Mcl-1 and the induction of the pro-apoptotic members, Bak, Bax, and Bim, which leads to mito-apoptosis [53].

4.2.4. Rg5 on tumors

The exposure to various concentrations of ginsenosides Rg5 (Rg5) for 24 h in esophageal cancer Eca109 cells decreases MMP via the downregulation of the PI3K-Akt signaling pathway [54]. Moreover, Rg5 remarkably suppresses breast cancer cell proliferation through mito-apoptosis and autophagic cell death by targeting the PI3K signaling pathway [55].

4.2.5. Other ginsenosides on tumors

In addition to the abovementioned ginsenosides, other ginsenosides can also target mitochondria to inhibit tumorigenesis and development. In human gastric carcinoma in vivo and in vitro models, ginsenoside F2 (F2) decreases MMP, and accelerates the release of Cyto C, which induces mitochondria-dependent apoptosis [56]. In human osteosarcoma MG-63 cells, RI induces G0/M phase cell cycle arrest and apoptosis through the mitochondrial apoptotic pathway [57]. In human leukemia K562 cells, Rg1 treatment at a concentration of 20 μM for 48 h inhibits dramatic morphological alterations, such as larger mitochondria and increased numbers of lysosomes [58]. In human gastric cancer SGC-7901 cells, pseudo-Rh2-induced apoptosis is associated with a decrease in MMP, downregulation of the Bcl-2/Bax ratio, and cleavages of caspase-9 and caspase-3 [59]. Furthermore, in a non-small cell lung cancer mouse xenograft model, ginsenosides Rk3 (Rk3) induces the activation of caspase-8, -9, and -3, promotes the change in MMP, decreases the Bcl2/Bax ratio and causes the release of Cyto C, which indicates that the apoptosis-inducing effect of Rk3 is triggered via mitochondria-mediated pathways [60].

In terms of tumor inhibition, CK and Rg3 are the most widely studied among ginsenoside monomers. Ginsenoside basically exerts its tumor-inhibitory effects by reducing MMP, increasing the release of Cyto C, and reducing the proportion of mitochondrial apoptotic pathways.

4.3. Heart disease

Heart diseases are characterized by persistent mitochondrial dysfunction. For example, during myocardial infarction, the supply of oxygen and energy is significantly compromised, and the mitochondrial structure in cardiomyocytes undergoes rapid changes, which cause heart functional damage: the suppression of OXPHOS, mainly due to the inhibition of complex I and/or ATP synthase, the loss of mitochondrial membrane integrity, due to the opening of mPTPs, and the release of Cyto C from mitochondria [61]. Numerous studies have shown that ginsenosides can target mitochondrial function, suppressing heart diseases (Table 3).

Mito-apoptosis plays a key role during myocardial I/R injury. In I/R-induced H9c2 cardiomyocytes, Rb1 can reduce mPTP by stabilizing MMP, leading to mito-apoptosis by reducing the release of Cyto C and the expression of cleaved caspase-3 in the cytoplasm, ultimately reducing programmed cell death [62]. In isolated rat hearts perfused with palmitate, high-fat diet-induced mice, and cardiomyocyte models, Rb1 prevents hypoxic succinate accumulation and improves pyruvate dehydrogenase (PDH) activity by blocking succinate-associated HIF-1α activation and GPR91 signaling, which ameliorates mitochondrial dysfunction and thereby reduces apoptosis during I/R [63]. In vivo and in vitro cardiomyocyte I/R injury models show that Rd pretreatment significantly stabilizes MMP, and attenuates cytosolic translocation of mitochondrial Cyto C and the activation of caspase-3/9, and increases the p-Akt or GSK-3β levels and the Bcl2/Bax ratio [64]. CK significantly inhibits mitochondrial swelling by partly mediating the activation of the PI3K pathway and phosphorylation of Akt in vivo I/R injured mouse models [65]. Under conditions with insufficient nutrients, Rg1 rescues ATP levels and MMP in nutrient-starved cells induced by glucose deprivation and in mice with nutritional stress via aldolase/AMPK/PINK1 signaling [66].

The dysfunction of mitochondrial dynamics (fusion/fission) is a prominent feature of ischemic heart disease [67]. Rg1 moderates glutamate dehydrogenase dysregulation, increases mitochondrial length, and Mfn2 expression to reduce the number of cells with fragmented mitochondria, and prevents the imbalance of mitochondrial dynamics following I/R [68]. Hexokinase-II (HK-II) and Drp1 differently regulate mitochondrial glucose metabolism and fission [69]. In cardiomyocyte I/R injury models and isoproterenol-induced ischemic mouse hearts, Rg5 improves PDH activity and ATP production, preventing the opening of mPTPs and mitochondrial fission via Drp1 recruitment and HK-II activation [70].

Sirtuin-1 (SIRT1), an NAD+-dependent histone deacetylase, plays a critical role in cellular metabolism, ETC function, and the response to oxidative stress in mitochondria [71]. Rb2, Fl1, and Rc can enhance the deacetylated activity of SIRT1 and increase ATP content, the oxygen consumption rate (OCR), and mtDNA copy number in tert-butyl hydroperoxide-induced H9c2 cardiomyocytes, suggesting that these ginsenosides attenuate oxidative stress-induced mitochondrial damage through the activation of SIRT1 [71]. In a myocardial infarction-induced heart failure mouse model and an I/R-induced H9c2 injury model, Rb3 treatment upregulates the levels of the mitochondrial deacetylase SIRT3 and peroxisome proliferator-activated receptor α, protecting mitochondrial membrane integrity [72].

4.4. Hyperglycemia

When the concentration of glucose in the blood exceeds normal levels, the mitochondria in muscle cells and neurons can undergo excessive fragmentation, leading to mito-ROS burst and damaging the integrity of mtDNA [73]. Furthermore, mitochondrial fission transmits mito-apoptotic signaling that increases the sensitivity of cells to undergo apoptosis, whereas the fusion of mitochondria can enhance cell survival [73]. In oral glucose (0.5 g/kg body weight)-treated rats, Rb1 (0.01 and 0.1 mg/kg body weight) increases postprandial glucose levels, citrate synthase activity, and glycogen content, whereas Rg1 (0.01 mg/kg body weight) decreased these indices in the red gastrocnemius muscle [74]. Meanwhile, both ginsenosides can influence mitochondria turnover dynamics and alter muscle metabolism [74]. Type II diabetes mellitus and metabolic syndrome are characterized by mitochondrial dysfunction accompanied by insulin resistance in skeletal muscle [75]. Kim et al. have shown that Rg3 treatment increases ATP production and the OCR and upregulates the levels of mitochondrial biosynthesis.
related proteins, including PGC1α, NRF-1, and complex IV/V, leading to an improvement of insulin resistance in skeletal muscle C2C12 cells [76]. Diabetic encephalopathy is a severe diabetic complication with characteristic symptoms of cognitive dysfunction and neuropsychiatric disability, which can be aggravated by mitochondrial dysfunction [77]. Rb1 could enhance the ratio of Bcl2 levels and Akt phosphorylation, and increased Bax expression of brown fat-related transcription factors, including NRF-1, and complex IV/V, leading to an improvement of insulin resistance in skeletal muscle C2C12 cells [82]. In an animal model of subcutaneous white adipose cells, Rd dominantly dissipates energy by non-shivering thermogenesis, whereas brown adipose tissue predominantly dissipates energy by non-shivering thermogenesis [83]. Mitochondria play a key role in energy homeostasis in adipose tissues. White adipose tissue primarily stores excess energy, whereas brown adipose tissue predominantly dissipates energy by non-shivering thermogenesis [84]. In an IL-1β-induced chondrocyte cell model of osteoarthritis, treatment with Rg1 for 2 h decreased IL-1β activity, reducing Bcl2 levels and Akt phosphorylation, and increased Bax activity, Cyto C release, and caspase-3 activation through PI3K/Akt signaling pathway [80]. In contrast, Rb1 showed an inhibition of MMP permeability and caspase-3 activity and increased Bcl-xl/Bax ratio in H2O2-induced rat articular chondrocytes [81]. Moreover, Rd remarkably inhibits the activation of the NLRP3 inflammasome, which is dependent on the mitochondrial translocation of p62 and mitophagy via regulation of the AMPK/ULK1 signaling pathway in a dextran sulfate sodium-induced murine colitis model [9].

5. Other disorders

Other diseases, such as obesity, myotube atrophy, and sepsis, have also been associated with the disruption of mitochondrial functions and homeostasis [82–84]. Mitochondria play a key role in energy homeostasis in adipose tissues. White adipose tissue primarily stores excess energy, whereas brown adipose tissue predominantly dissipates energy by non-shivering thermogenesis [85]. In an animal model of subcutaneous white adipose cells isolated from C37BL/6 mice and 3T3-L1 adipocytes, UCP1 expression and mitochondrial biogenesis are upregulated by Rg1 via AMPK signaling pathway, which suggests that Rg1 exerts its anti-obesity effect by promoting adipocyte browning [86]. In addition, Rb1 promotes the browning of 3T3-L1 adipocytes by increasing basal glucose uptake and energy production, and upregulating the expression of brown fat-related transcriptional factors, including UCP-1, PGC-1α, and zinc finger protein 16 [87].

Mitochondrial function also influences virus propagation and adaptation through morphology changes mediated by mitochondrial fusion and fission [89]. Kim et al. demonstrated that Rg3 inhibits hepatitis C virus (HCV) propagation by restoring the Drp1-mediated aberrant mitochondrial fission and mitophagy, thereby suppressing HCV infection [89]. In addition, in vitro and in vivo sepsis models, Rg3 shows beneficial functions, such as OCR protection, ROS attenuation, and maintaining the maintenance of GSH pools, by regulating AMPK-mediated mitophagy [90].

Multiple stimulations, such as UV, elevated glucose, particulate matter of 2.5 μm and smaller (PM2.5), and H2O2 can increase mitochondrial ROS production and oxidative stress damage, which are associated with the depressed activity of the mitochondrial respiratory chain. In UV-irradiated normal human dermal fibroblast cells, Rg3 restores mitochondrial ATP levels and MMP, which leads to an increase in proteins linked with extracellular matrix, cell proliferation, and antioxidant activity [91]. In high glucose-induced rat retinal capillary endothelial cells, treatment with Rb1 significantly increases cell viability and mtDNA copy number, and inhibits ROS burst through the up-regulation of SIRT1 and SIRT3 expression [92]. In PM2.5-induced human HaCaT keratinocytes and normal dermal fibroblasts, Rb1 restores the production of ATP and blocks ER stress via the mitochondrial pathway [93]. Proteomic analysis has shown that 23 proteins spots are upregulated by Re pretreatment, which are mainly involved in the restoration of mitochondrial functions in H2O2-induced human umbilical vein endothelial cells [94]. In particular, in isolated spinal cord mitochondria, Rd regulates mPTP formation, Cyto C release, mitochondrial swelling, and NAD(P)/H matrix content through Akt and ERK pathways [95].

Overall, emerging evidences has shown that several ginsenosides can target mitochondria to treat different diseases through multiple mitochondria-related signaling pathways (Fig. 3).

5. Conclusion and perspective

Ginsenosides have attracted much attention based on a wide range of pharmacological effects and medical applications. In the present review, we summarized recent findings about major ginsenosides from P. ginseng targeting mitochondrial function, hoping to partially explain the common targets of ginsenosides against multiple diseases. Currently, a huge body of pre-clinical studies aim to evaluate the protective/therapeutic effects of several ginsenosides, such as Rd, and Rb1, which cannot explore the molecular mechanism of these ginsenosides [96,97]. In the future, our missions mainly contain two directions as below: one is to explore the potential targets or molecular networks of ginsenosides, and the other is to investigate the synergistically function of various ginsenosides as a mixture from ginseng extracts against a variety of diseases. Extensive and
deep studies for ginsenosides targeting mitochondrial function could provide new insights into the clinical therapeutic application of *P. Ginseng* against multiple disorders.

**Conflicts of interest**

The authors have declared no conflict of interest.

**Acknowledgments**

This work was supported by the National Key Research and Development Program of China (No. 2017YFC1702103, 2019YFC1709901), Regional Innovation and Development Joint Fund (U19A2013), National Natural Science Foundation of China (81602257), the Science and Technology Development Plan Project of Jilin Province (No. 20190101010JH, 202002053JC), Jilin Provincial Administration of Traditional Chinese Medicine (2020168) and the Project for Science and Technology Bureau of Changchun (No. 18YJ013).

**References**

[1] Qi HY, Li L, Ma H. Cellular stress response mechanisms as therapeutic targets of ginsenosides. Medicinal Research Reviews 2018;38:625–54.

[2] Zheng Q, Bao X-Y, Zhu P-C, Tong Q, Zheng G-Q, Wang Y. Ginsenoside Rb1 for myocardial ischemia/reperfusion injury: preclinical evidence and possible mechanisms. Oxidative Medicine and Cellular Longevity 2017;10:1–14.

[3] Wang C, Liu J, Deng J, Wang J, Weng W, Chu H, et al. Advances in the chemistry, pharmacological diversity, and metabolism of 20(R)-ginsenoside saponins. Journal of Ginseng Research 2020;44:14–23.

[4] Boyman L, Karbowski M, Lederer WJ. Regulation of mitochondrial ATP production: Ca(2+) signaling and quality control. Trends in Molecular Medicine 2020;26:21–39.

[5] Bock RJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nature Reviews Molecular Cell Biology 2020;21:85–100.

[6] Rajabian A, Rameshkar M, Hosseinzadeh H. Therapeutic potential of Panax ginseng and its constituents, ginsenosides and gintonin, in neurological and neurodegenerative disorders: a patent review. Expert Opinion on Therapeutic Patents 2019;29:55–72.

[7] Jin X, Zhou J, Zhang Z, Lv H. The combined administration of parthenolide and ginsenoside CK in lung circulation liposomes with targeted tlyp-1 ligand induce mitochondria-mediated lung cancer apoptosis. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:5931–42.

[8] Zhou P, Xie W, Sun Y, Dai Z, Li G, Sun G, et al. Ginsenoside Rb1 and mitochondria: a short review of the literature. Molecular and Cellular Probes 2019;43:1–5.

[9] Liu C, Wang J, Yang Y, Liu X, Zhou Y, Zhang J, et al. Ginsenoside Rb1 ameliorates colitis by inducing p62-driven mitophagy-mediated NLRP3 inflammasome inactivation in mice. Biomedical Pharmacology 2018;155:66–79.

[10] Ong WY, Farooqui T, Koh HL, Farooqui AA, Ling EA. Protective effects of ginseng on neurological disorders. Frontiers in Aging Neuroscience 2015;7:129.

[11] Baek SH, Rae ON, Park JH. Recent methodology in ginseng analysis. J Ginseng Res 2012;36:119–34.

[12] Liu L, Anderson GA, Fernandez TG, Dore S. Efficacy and mechanism of Panax ginseng in experimental stroke. Frontiers in Neuroscience 2019;13:294.

[13] Pfanner N, Warscheid B, Wiedemann N. Mitochondrial proteins: from biogenesis to functional networks. Nature Reviews Molecular Cell Biology 2019;20:267–84.

[14] Murphy MP, Hartley RC. Mitochondria as a therapeutic target for common pathologies. Nature Reviews Drug Discovery 2018;17:865–86.

[15] Lin J, Huang HF, Yang SK, Duan J, Qi SM, Yuan R, et al. The effect of Ginsenoside Rg1 in hepatic ischemia reperfusion (I/R) injury ameliorates ischemia-reperfusion-induced liver injury by inhibiting apoptosis. Biomedicine & Pharmacotherapy – Biomedecine & Pharmacotherapie 2020;129:110398.

[16] Hou J, Jin Y, Xue J, Jeon B, Kim S. Doxorubicin-induced normal breast epithelial cellular aging and its related breast cancer growth through...
mitochondrial autophagy and oxidative stress mitigated by ginsenoside Rg2. *Phytotherapy Research* : PTR 2020;34:1659–63.

[17] Duarte AC, Meira CA, Mongeon R, Lahnema KH, Koval D, Zucker R, Yellen G. Neuronal stimulation triggers neuronal glycolysis and not lactate uptake. *Cell Metabolism* 2017;26:361–374 e4.

[18] Siddiqui SA, Datta S, Tang A, Liu L, Ross CA, Baldo MA. Magnetic domain wall based synaptic function and synaptic function generator for neuroimplantable applications. *Nano Letters* 2020;20:1033–40.

[19] Liu Y, Zhang RY, Zhao J, Dong Z, Feng DY, Wu R et al. Ginsenoside Rd protects SH-SY5Y cells against 1-Methyl-4-phenylpyridinium induced injury. *International Journal of Molecular Sciences* 2015;16:4395–408.

[20] Zhang Y, Yang X, Wang S, Song S. Ginsenoside Rg3 prevents cognitive impairment by improving mitochondrial dysfunction in the rat model of Alzheimer’s disease. *Journal of Agricultural and Food Chemistry* 2015;63:4085–91.

[21] Ye R, Kong X, Yang Q, Zhang Y, Han J, Zhao G. Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice. *Neuropharmacology* 2011;61:815–24.

[22] Gonzalez-Burgos E, Fernandez-Moriano C, Lozano R, Iglesias I, Gomez-Serranillos MP. Ginsenosides Rd and Re co-treatments improve rotenone-induced oxidative stress and mitochondrial impairment in SH-SY5Y neuroblastoma cells. *Food and Chemical Toxicology : Food and Chemical Toxicology* : An International Journal Published for the British Industrial Biological Research Association 2017;109:38–47.

[23] Shim JS, Song MY, Yim SV, Lee SE, Park KS. Global analysis of ginsenoside Rg1 protective effects on beta-amylotoxid-treated neuronal cells. *Journal of Ginseng Research* 2017;41:566–76.

[24] Wu J, Yang H, Zhao Q, Zhang X, Lou Y. Ginsenoside Rg1 exerts a protective effect against A beta(25-35)-induced toxicity in primary cultured rat cortical neurons through the NF-kappab/NO pathway. *International Journal of Molecular Medicine* 2016;37:781–8.

[25] Liu M, Bai X, Yu S, Zhao W, Qiao J, Liu Y et al. Ginsenoside Re inhibits ROS/ASK-1 dependent mitochondrial apoptosis pathay and activation of nf23-dependent response in beta-amylotoxid-challenged SH-SY5Y cells. *Molecules* 2019;24:25.

[26] Yang LX, Zhang X, Zhao G. Ginsenoside Rd attenuates DNA damage by increasing expression of DNA glycosylase endonuclease VIII-like proteins after focal cerebral ischemia. *Chinese Medical Journal* 2016;129:1955–62.

[27] Ye R, Zhang X, Kong X, Han J, Yang Q, Zhang Y et al. Ginsenoside Rd attenuates mitochondrial dysfunction and sequential apoptosis after transient focal ischemia. *Neuroscience* 2011;178:169–80.

[28] Xu M, Ma Q, Fan F, Ding J, Li X, Zhang M. Ginsenosides Rb1 and Rg1 protect primary cultured astrocytes against oxygen-glucose deprivation-reoxygenation-induced injury via improving mitochondrial function. *International Journal of Molecular Sciences* 2019;20:23.

[29] Tran TV, Shin EJ, Dang DK, Lee SE, Park KS. Global analysis of ginsenoside Rg1 protective effects on beta-amylotoxid-treated neuronal cells. *Journal of Ginseng Research* 2017;41:566–76.

[30] Shim JS, Song MY, Yim SV, Lee SE, Park KS. Global analysis of ginsenoside Rg1 protective effects on beta-amylotoxid-treated neuronal cells. *Journal of Ginseng Research* 2017;41:566–76.

[31] Liu Y, Fan D. The preparation of ginsenoside Rg5, its antitumor activity against human lung cancer A549 cells and the mechanism of apoptosis induction. *Acta pharmacologica sinica* 2007;28:828–37.

[32] Liu J, Cai SZ, Zhou Y, Zhang XP, Liu DF, Jiang R et al. Senescence as a consequence of ginsenoside Rg1 response on k562 human leukemia cell line. *Asian Journal of Pharmaceutical Research* 2013;3:31–44.

[33] Rak DH, Kim HD, Kim YO, Park CG, Han SY, Kim J. Neuroprotective effects of 20(S)-propanaxanol against glutamate-induced mitochondrial dysfunction in PC12 cells. *International Journal of Molecular Medicine* 2016;37:378–86.

[34] Jiang GZ, Li J. Protective effects of ginsenoside Rg1 against colinitin sulfate-induced apoptosis in PC12 cells. *Cell Mol Neurobiol* 2014;34:167–73.

[35] Liu D, Zhang H, Gu W, Liu Y, Zhang M. Neuroprotective effects of ginsenoside Rb1 on high glucose-induced toxicity in primary cultured rat hippocampal neurons. *PlcOx 2013;13:8; 79399.

[36] Fernandez-Moriano C, Gonzalez-Burgos E, Iglesias I, Lozano R, Gomez-Serranillos MP. Evaluation of the adaptogenic potential exerted by ginsenosides Rb1 and Rg1 against oxidative stress-mediated neurotoxicity in an in vitro neurotoxic model. *Neurotox Res* 2017;12:0182993.

[37] Oh JM, Kim E, Cimino E, Girev D, Sanchez J. Cultured human hippocampal neurons exhibit high glutamate and glycine uptake and increase ROS levels in response to ginsenoside Rg5. *J Neurochem* 2019;140:6046409.

[38] Li J, Yang YL, Li L, Zhang L, Liu Q et al. Succinate accumulation impairs cardiac pyruvate dehydrogenase activity through GRP91-dependent and independent signaling pathways: therapeutic effects of ginsenoside Rb1. *Biochemistry and Cell Biology* 2018;96:2835–47.

[39] Wang Y, Li X, Wang X, Lau W, Wang Y, Xing Y et al. Ginsenoside Rd attenuates myocardial ischemia/reperfusion injury via Akt/GSK-3beta signaling and inhibition of the mitochondria-dependent apoptotic pathway. *Phyto 2013;8: 379955.
Ginsenosides regulate mitochondrial function to treat various diseases

Q. Huang, S. Gao, D. Zhao et al.

[65] Tsutsui YM, Tsutsui R, Mawatari K, Nakaya Y, Kinoshita M, Tanaka K, et al. Compound K, a metabolite of ginsenosides, induces cardiac protection mediated nitric oxide via Akt/PI3K pathway. Life Sciences 2011;88:725–9.

[66] Xu Z, Li C, Liu Q, Yang H, Li P. Ginsenoside Rg1 protects H9c2 cells against nutritional stress-induced injury via aldolase/AMPK/PINK1 signalling. Journal of Cellular Biochemistry 2019;120:18388–97.

[67] Bagur R, Tanguy S, Forel S, Grichine A, Sanchez C, Pernet-Gallay K, et al. The impact of cardiac ischemia/reperfusion on the mitochondria-cytokleton interactions. Biochimica et biophysica acta 2016;1862:1159–71.

[68] Dong G, Chen T, Ren X, Zhang Z, Huang W, Liu L, et al. Rg1 prevents myocardial hypoxia/reoxygenation injury by regulating mitochondrial dynamics imbalance via modulation of glutamate dehydrogenase and mitofusin 2. Mitochondrion 2016;26:7–18.

[69] Bi J, Zhang J, Ren Y, Du Z, Li Q, Wang Y, et al. Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress. Redox Biology 2019;20:296–306.

[70] Yang YL, Li J, Liu K, Zhang L, Liu Q, Liu B, et al. Ginsenoside Rg5 increases cardiomyocyte resistance to ischemic injury through regulation of mitochondrial hexokinase-II and dynamin-related protein 1. Cell Death & Disease 2017;8:e2625.

[71] Wang Y, Liang X, Chen Y, Zhao X. Screening SIRT1 activators from medicinal plants as bioactive compounds against oxidative damage in mitochondrial function. Oxidative Medicine and Cellular Longevity 2016;2016:4206392.

[72] Chen X, Wang Q, Shao M, Ma L, Guo D, Wu Y, et al. Ginsenoside Rb3 regulates energy metabolism and apoptosis in cardiomyocytes via activating PPAr/alpha pathway. Biomedicine & Pharmacotherapy – Biomediene & Pharmacotherapie 2019;120:109487.

[73] Zorov DB, Vorobjev IA, Popkov VA, Babenko VA, Zorova LD, Pevzner IB, et al. Lessons from the discovery of mitochondrial fragmentation (fission): a review and update. Cells 2019;8:2.

[74] Chaunchaiyakul R, Leelayuwat N, Wu JF, Huang CY, Kuo CH. Contrasting acute inflammation and disease progression. Trends in Immunology 2018;39:8.

[75] Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological Reviews 2018;98:2133–223.

[76] Kim MJ, Koo YD, Kim M, Lim S, Park YJ, Chung SS, et al. Rg3 improves mitochondrial function and the expression of key genes involved in mitochondrial biogenesis in C2C12 myotubes. Diabetes & Metabolism Journal 2016;40:406–13.

[77] Quansah E, Pellaerts W, Langston JW, Simon DK, Colca J, Brundin P. Targeting associated endoplasmic reticulum stress: protective effects of ginsenoside Rb1. Antioxidants 2019;8:9.

[78] Fan C, Ma Q, Xu M, Qiao Y, Yang Z, Li P, et al. Ginsenoside Rb1 attenuates high glucose-induced oxidative injury via the NAD-PARP-SIRT Axis in rat retinal capillary endothelial cells. International Journal of Molecular Sciences 2019;20:19.

[79] Piao MJ, Kang KA, Zhen AX, Fernando P, Ahn MJ, Koj YS, et al. Particulate matter 2.5 mediates cutaneous cellular injury by inducing mitochondria-associated endoplasmic reticulum stress: protective effects of ginsenoside Rb1. Antioxidants 2019;8:9.

[80] Huang GD, Zhong XF, Deng ZY, Zeng R. Proteomic analysis of ginsenoside Re attenuates hydrogen peroxide-induced oxidative stress in human umbilical vein endothelial cells. Food & Function 2016;7:2451–61.

[81] Zhou JS, Wang JP, He BR, Cui YS, Fang XY, Ni JL, et al. Ginsenoside Rd attenuates mitochondrial permeability transition and cytochrome C release in isolated spinal cord mitochondria: involvement of kinase-mediated pathways. International Journal of Molecular Sciences 2014;15:9859–77.

[82] Liu X, Wang L, Wen A, Yang J, Yan Y, Song Y, et al. Ginsenoside-Rd improves outcome of acute ischemic stroke - a randomized, double-blind, placebo-controlled, multicenter trial. European Journal of Neurology 2012;19:855–63.

[83] Xu X, Lu Q, Wu J, Li Y, Sun J. Impact of extended ginsenoside Rb1 on early chronic kidney disease: a randomized, placebo-controlled study. Inflammopharmacology 2017;25:33–40.